Please login to the form below

Not currently logged in
Email:
Password:

Oxford BioMedica appoints Tim Watts chief financial officer

He also takes up the role of company secretary at the UK biopharmaceutical company

Tim Watts has joined UK-based biopharmaceutical company Oxford BioMedica as its chief financial officer (CFO) and company secretary.

Watts takes over from outgoing CFO Andrew Wood and moves to the firm from Archimedes Pharma, where he also held the role of CFO.

Oxford BioMedica said that Wood would continue to work at the company for the time being to ensure the smooth transition between the new and old CFOs.

The company's CEO John Dawson said: "We thank Andrew for his substantial contribution to Oxford Oxford BioMedica BioMedica since its IPO in 1996. His commitment to the company has been invaluable and we wish him well for the future.

“I would like to welcome Tim to the executive management team and am confident that his expertise will support Oxford BioMedica's strategy to secure corporate and commercial success."

Watts over 30 years' experience in leading multinational and entrepreneurial businesses.

In 1985 he joined ICI, initially in the corporate headquarters and then from 1990 in the pharmaceuticals division, where he rose to be finance director of the Zeneca Pharmaceuticals business.

Following the merger of 1998 merger of Astra and Zeneca, Tim continued at the newly combined company and in 2001 became group financial controller of AstraZeneca.

16th February 2012

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics